Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer: Long-term results

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 1, 1996, Pages 10-17

  Colozza, M ^a   Gori, S ^a   Mosconi, A M ^a   Anastasi, P ^a   De Angelis, V ^b   Giansanti, M ^b   Mercati, U ^c   Aristei, C ^a   Latini, P ^a   Tonato, M ^a  

^a Policlinico Hospital   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Ospedale Silvestrini   (Italy)

Author keywords

Breast cancer; Combined treatment; Induction chemotherapy; Locally advanced

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; MASTECTOMY, RADICAL; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE;

EID: 9044244912     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199602000-00003     Document Type: Article

References (49)

1. Fracchi AA, Evans JF, Eisenberg BL. Stage III carcinoma of the breast. Ann Surg 1980;192:705-10.
2. International Union Against Cancer (UICC). TNM classification of malignant tumors. New York: Springer-Verlag, 1983.
3. Haagensen CD. The clinical classification of carcinoma and the choise of treatment. In: Haagensen CD, ed. Disease of the breast. Philadelphia: WB Saunders; 1971:617-68.
4. Pearlman NW, Guerra O, Fracchia AA. Primary inoperable cancer of the breast. Surg Gynecol Obstet 1976;143:909-13.
5. Langlands AO, Kerr GR, Shaw S. The management of locally advanced breast cancer by x-ray therapy. Clin Oncol 1976;2: 365-71.
6. Treurnift-Donker AD, Hop WCJ, Hoed-Sijtsema S. Radiation treatment of stage III mammary carcinoma: A review of 129 patients. Int J Radiat Oncol Biol Phys 1980;6:1477-82.
7. Almaric R, Santamaria F, Robert F. Radiation therapy with or without primary limited surgery for operable breast cancer. Cancer 1982;49:30-34.
8. Bruckman JE, Harris JR, Levene MB, et al. Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer 1979;43:985-93.
9. Zucali R, Uslenghi C, Kenda R, et al. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer 1976;37:1422-31.
10. Balawajder I, Antich PP, Boland J. An analysis of the role of radiotherapy alone in combination with chemotherapy and surgery in the management of advanced breast carcinoma. Cancer 1983;51:574-80.
11. Rubens RD, Armitage P, Winter PJ, et al. Prognosis in inoperable stage III carcinoma of the breast. Eur J Cancer 1977;13:805-11.
12. Bedwinek J, Rao DV, Perez C, et al. Stage III and localized stage IV breast cancer: irradiation alone versus irradiation plus surgery. Int J Radiat Oncol Biol Phys 1982;8:31-6.
13. Wiseman C, Jessup J, Smith T, et al. Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/ BCG immunotherapy. Cancer 1982;49:1266-71.
14. Zylberberg B, Sala-Baroux J, Ravina J, et al. Initial chemoimmunotherapy in inflammatory carcinoma of the breast. Cancer 1982;49:1537-43.
15. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-24.
16. Schwain SM, Lippman ME. Treatment of patients with inflammatory breast cancer. Important Adv Oncol 1989:129-50.
17. Hortobagyi G, Blumenschein G, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51:763-8.
18. Swain S, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced non-metastatic breast cancer. Cancer Res 1987;47:3889-94.
19. Rubens RD, Bartelink H, Engelsman E, et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. Eur J Cancer Clin Oncol 1989;25:667-78.
20. Schaake-Konig C, Van der Linden EH, Hart G, et al. Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys 1985;11:1759-63.
21. Kolaric K, Roth A. Phase II clinical trial of cis-dichlorodiamineplatinum (cis-ddp) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983;11:108-12.
22. Kolaric K, Roth A, Vukas D, et al. CAP (cyclophosphamide, adriamycin, platinum) vs. CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer: a preliminary report of a controlled clinical study. Cancer Chemother Pharmacol 1984;13:142-4.
23. Kolaric K, Vukas D, Potrebica V. CAP (cyclophosphamide, adriamycin, platinum) vs. FAC (5-fluorouracil, adriamycin, cyclophosphamide) combination chemotherapy in untreated metastatic breast cancer: a preliminary report. [Abstract]. Proc Am Soc Clin Oncol 1986;5:77.
24. Colozza M, Gori S, Mosconi AM, et al. Chemotherapy with cisplatin, doxorubicin and cyclophosphamide (CAP) in patients with metastatic breast cancer. Am J Clin Oncol 1989;12:137-41.
25. De Lena M, Brandi M, Logroscino A, et al. Intravenous administration of cyclophosphamide, methotrexate, and 5-fluorouracil in metastatic breast cancer: a pilot study. Tumori 1988;74:57-63.
26. Roila F, Tonato M, Basurto C, et al. Protection from nausea and vomiting in cisplatin-treated patients; high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and difenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 1989;7:1693-700.
27. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
28. Roila F, Basurto C, Minotti V, et al. A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 1986;18:88-9.
29. Longo DL, Duffey PL, De Vita VT Jr, et al. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991;9:2042-51.
30. Pisansky TM, Schaid DJ, Loprinzi CL, et al. Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol 1992;15:376-87.
31. Venkata DR, Bedwinek J, Perez C, et al. Prognostic indicators in stage III and localized stage IV breast cancer. Cancer 1982;50: 2037-43.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81.
33. Marubini E, Valsecchi MG. Analisi della sopravvivenza in sperimentazioni cliniche controllate e nelle osservazioni pianificate. Monografia n.9, 1987. Collana a cura del "Centro Zambon" dell'Università di Milano.
34. SAS/STAT user's guide, version 6, 4th Ed. SAS Institute Inc, Cary, NC, 1989.
35. Torrecillas L, Cervantes G, Gomez E, et al. Analysis of clinical vs pathological response in locally advanced breast cancer after FAC or FEC neoadjuvant chemotherapy. Proc Am Soc Clin Oncol 1993;12:142.
36. Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46:2578-81.
37. De Lena M, Zucali R, Viganotti G, et al. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-9.
38. De Lena M, Varini M, Zucali R, et al. Multimodal treatment for locally advanced breast cancer. Cancer Clin Trials 1981;4: 229-36.
39. Valagussa P, Zambetti M, Bonadonna G, et al. Prognostic factors in locally advanced inflammatory breast cancer: long-term results following primary chemotherapy. Breast Cancer Res Treat 1990;15:137-47.
40. Grohn P, Heinonen E, Klefstrom P, et al. Adjuvant postoperative radiotherapy, chemotherapy and immunotherapy in stage III breast cancer. Cancer 1984;54:670-4.
41. De Lena M, Viganotti G, Varini M, et al. Multimodal treatment for locally advanced breast cancer. Results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 1981;4:229-36.
42. Lesnick G, Perloff M, Korzun A, et al. Combination chemotherapy prior to surgery or radiotherapy in locally advanced breast cancer. In: Jacquillat C, Weil M, Khayat D, eds. Neo-Adjuvant Chemotherapy Second International Congress. Paris: John Libbey Eurotext; 1986:207-11.
43. Bedwinek J, Roo DV, Perez C, et al. Stage III and localized stage IV breast cancer: irradiation alone versus irradiation plus surgery. J Radiat Oncol Biol Phys 1982;8:31-6.
44. Hortobagyi G, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 1988;62:2507-16.
45. Piccart MJ, De Valeriola D, Paridaens R, et al. Six-year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer 1988;62:2501-6.
46. Buzdar AU, Kau SW, Smith TL, et al. The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. Cancer 1993;71:3680-4.
47. Buchholz TA, Austin-Seymour MM, Moe RE, et al. Effect of delay irradiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 1993;26:23-35.
48. Hortobagyi GN: Is cis-platin useful for breast cancer? Eur J Cancer Clin Oncol 1987;23:119-21.
49. Martino S, Samal BA, Singhakowinta A. A phase II study of cisdiamminodichloroplatinum II for advanced breast cancer: two dose schedules. J Cancer Res Clin Oncol 1984;108:354-6.